nach oben

Erschienen in:

17.04.2017 | Original Article

Levels of cystatin C in low- and high-flux hemodialysis in children with end-stage renal disease

verfasst von: Fatina I. Fadel, Abbass A. Mourad, Azza M. O. Abdel Rahman, Hafez M. Bazaraa, Mohamed Farouk Mohamed, Dalia H. El-Lebedy, Mohamed M. Soliman

Erschienen in: Pediatric Nephrology | Ausgabe 9/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Cystatin-C (CyC) is a middle molecule that is freely filtered at the glomerulus and almost completely reabsorbed by the proximal tubules. The aim of this study was to evaluate serum CyC and its reduction ratio as a biomarker for assessing the adequacy of the hemodialysis (HD) sessions in children with end-stage renal disease on maintenance HD. We also compared levels of CyC in patients on low-flux HD (LFH) and high-flux HD (HFH).

Methods

Forty patients were included in the study and divided into two groups, with one group (16 patients) receiving HFH and the other group receiving LFH (24 patients) (high-flux and low-flux polysulfone filters, respectively). Before and after each dialysis session serum CyC and beta-2-microglobulin (B2M) levels were measured using an ELISA technique, and routine laboratory tests were performed for each patient.

Results

Pre-dialytic levels of CyC were significantly lower in the patients receiving HFH than in those receiving LFH (7.33 ± 1.35 vs. 9.73 ± 0.93, respectively; p < 0.0001). In the HFH group, post-dialytic levels of serum CyC were significantly lower than pre-dialytic levels (4.49 ± 0.71 vs. 7.33 ± 1.35, respectively; p < 0.0001). The reduction ratio (RR) of CyC was significantly higher in the HFH group than in the LFH group (38.2 ± 3.91 vs. −6.49 ± 5.05, respectively; p < 0.0001). Serum CyC level significantly correlated with B2M, urea and creatinine levels in both the LFH and HFH groups, whereas its RR significantly correlated with the RRs of urea, creatinine, and B2M in the HFH group.

Conclusion

The results of our study emphasize the role of CyC as a good marker for assessing the adequacy of HD sessions in children on HFH and show that the CyC RR may be used as an index of middle-molecule toxin clearance following HFH sessions.

Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Herzog C, Ishani A, Johansen K, Kasiske B, Kutner N, Liu J, St Peter W, Ding S, Guo H, Kats A, Lamb K, Li S, Li S, Roberts T, Skeans M, Snyder J, Solid C, Thompson B, Weinhandl E, Xiong H, Yusuf A, Zaun D, Arko C, Chen SC, Daniels F, Ebben J, Frazier E, Hanzlik C, Johnson R, Sheets D, Wang X, Forrest B, Constantini E, Everson S, Eggers P, Agodoa L (2013) US Renal Data System 2012 annual data report. Am J Kidney Dis 61[1 Suppl 1]:A7, e1-e476

Vanholder RC, Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J (2008) A bench to bedside view of uremic toxins. J Am Soc Nephrol 19(5):863–870CrossRefPubMed

National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39[Suppl 1]:S1–S266

Bouré T, Vanholder R (2004) Whichdialyser membrane to choose? Nephrol Dial Transplant 19(2):293–296CrossRefPubMed

Tattersall J, Canaud B, Heimburger O, Pedrini L, Schneditz D, Van Biesen W (2010) High-flux or low-flux dialysis: a position statement following publication of the membrane permeability outcome study. Nephrol Dial Transplant 25(4):1230–1232CrossRefPubMed

Dixit MP, Cabansag MR, Piscitelli J, Greifer I, Silverstein DM (1999) Serum beta2-microglobulin and immunoglobulin levels in young hemodialysis patients. Pediatr Nephrol 13(2):139–142CrossRefPubMed

Huang SH, Filler G, Yasin A, Lindsay RM (2011) Cystatin C reduction ratio depends on normalized blood liters processed and fluid removal during hemodialysis. Clin J Am Soc Nephrol 6(2):319–325CrossRefPubMedPubMedCentral

Schwartz GJ, Schneider MF, Maier PS, Moxey-Mims M, Dharnidharka VR, Warady B, Furth SL, Muñoz A (2012) Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C. Kidney Int 82(4):445–453CrossRefPubMedPubMedCentral

Campo A, Lanfranco G, Gramaglia L, Goia F, Cottino R, Giusto V (2004) Could plasma cystatin C be useful as a marker of hemodialysis low molecular weight proteins removal? Nephron Clin Pract 98(3):c79–c82CrossRefPubMed

10.

Marsenic O, Wierenga A, Wilson DR, Anderson M, Shrivastava T, Simon GA, Beck AM, Swanson TJ, Studnicka K, Elberg D, Couloures K, Turman MA (2013) Cystatin C in children on chronic hemodialysis. Pediatr Nephrol 28:647–653CrossRefPubMed

11.

Kolodziejczyk R, Michalska K, Hernandez-Santoyo A, Wahlbom M, Grubb A, Jaskolski M (2010) Crystal structure of human cystatin C stabilized against amyloid formation. FEBS J 277(7):1726–1737CrossRefPubMed

12.

Vilar E, Boltiador C, Wong J, Viljoen A, Machado A, Uthayakumar A, Farrington K (2015) Plasma levels of middle molecules to estimate residual kidney function in Haemodialysis without urine collection. PLoS One 10(12):e0143813CrossRefPubMedPubMedCentral

13.

Finney H, Newman DJ, Thakkar H, Fell JM, Price CP (2000) Reference ranges for plasma cystatin C and creatinine measurements in premature infants, neonates, and older children. Arch Dis Child 82(1):71–75CrossRefPubMedPubMedCentral

14.

Flodin M, Hansson LO, Larsson A (2006) Variations in assay protocol for the Dako cystatin C method may change patient results by 50% without changing the results for controls. Clin Chem Lab Med 44(12):1481–1485CrossRefPubMed

15.

Dworkin LD (2001) Serum cystatin C as a marker of glomerular filtration rate. Curr Opin Nephrol Hypertens 10(5):551–553CrossRefPubMed

16.

Menon V, Shlipak MG, Wang X, Coresh J, Greene T, Stevens L, Kusek JW, Beck GJ, Collins AJ, Levey AS, Sarnak MJ (2007) Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann Intern Med 147:19–27CrossRefPubMed

17.

Vanholder RC, Glorieux GL, De Smet RV (2003) Back to the future: middle molecules, high flux membranes and optimal dialysis. Hemodial Int 7(1):52–57CrossRefPubMed

18.

Liabeuf S, Lenglet A, Maheshwari KU, Santhi S, Malar RJ (2015) Cystatin C: an alternative dialysis adequacy marker in high flux hemodialysis. Indian J Nephrol 25(3):143–145CrossRef

19.

Vilar E, Boltiador C, Viljoen A, Machado A, Farrington K (2014) Removal and rebound kinetics of cystatin C in high-flux hemodialysis and hemodiafiltration. Clin J Am Soc Nephrol 9(7):1240–1247CrossRefPubMedPubMedCentral

20.

Micle O, Vicas SI, Ratiu I, Vicas L, Muresan M (2015) Cystatin C, a low molecular weight protein in chronic renal failure. Farmacia 63(6):872–876

21.

Li Y, Wang Y, Lv J, Wang M (2013) Clinical outcomes for maintenance hemodialysis patients using a high-flux (FX60) dialyzer. Ren Fail 35(9):1240–1245CrossRefPubMed

22.

Chavers BM, Solid CA, Daniels FX, Chen SC, Collins AJ, Frankenfield DL, Herzog CA (2009) Hypertension in pediatric long-term hemodialysis patients in the United States. Clin J Am Soc Nephrol 4(8):1363–1369CrossRefPubMedPubMedCentral

23.

Susantitaphong P, Siribamrungwong M, Jaber BL (2013) Convective therapies versus low-flux hemodialysis for chronic kidney failure: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 28(11):2859–2874CrossRefPubMed

24.

Ram CV, Fenves AZ (2009) Management of hypertension in hemodialysis patients. Curr Hypertens Rep 11(4):292–298CrossRefPubMed

25.

Krishnamurthy N, Arumugasamy K, Anand U, Anand CV, Aruna V, Venu G, Gayathri R (2010) Effect of hemodialysis on circulating cystatin c levels in patients with end stage renal disease. Indian J Clin Biochem 25(1):43–46CrossRefPubMedPubMedCentral

26.

Kabanda A, Jadoul M, Pochet JM, Lauwerys R, van Ypersele de Strihou C, Bernard A (1994) Determinants of the serum concentrations of low molecular weight proteins in patients on maintenance hemodialysis. Kidney Int 45(6):1689–1696CrossRefPubMed

27.

Monitini G, Amici G, Milan S, Mussap M, Naturale M, Rätsch IM, Ammenti A, Sorino P, Verrina E, Andreetta B, Zacchello G; on behalf of the Italian Registry of Pediatric Peritoneal Dialysis (2002) Middle molecule and small protein removal in children on peritoneal dialysis. Kidney Int 61(3):1153–1159

28.

Park JS, Kim GH, Kang CM, Lee CH (2010) Application of cystatin-C reduction ratio to high-flux hemodialysis as an alternative indicator of the clearance of middle molecules. Korean J Intern Med 25(1):77–81CrossRefPubMedPubMedCentral

29.

Marsenic O, Wierenga A, Wilson DR, Anderson M, Shrivastava T, Simon GA, Beck AM, Swanson TJ, Studnicka K, Elberg D, Singh NS, Couloures K, Henry D, Turman MA (2013) Comparison of cystatin C and beta-2-microglobulin kinetics in children on maintenance hemodialysis. Hemodial Int 17[Suppl 1]:S11–S16CrossRefPubMed

30.

Cristofano C, Vernaglione L, Perniola MA, Lo Barco C, Muscogiuri P, Chimienti S (2004) Cystatin C, beta2-microglobulin and C-reactive protein in hemodiafiltration and on-line endogenous liquid reinfusion and in low flux polysulphone bicarbonate conventional hemodialysis. G Ital Nefrol 21[Suppl 30]:S197–S200PubMed

31.

Gökkuşu CA, Ozden TA, Gül H, Yildiz A (2004) Relationship between plasma cystatin C and creatinine in chronic renal diseases and Tx-transplant patients. Clin Biochem 37(2):94–97CrossRefPubMed

32.

Khorgami Z, Abdollahi A, Soleimani S, Ahmadi F, Mahdavi-Mazdeh M (2013) Relationship between serum cystatin C and creatinine or dialysis adequacy in patients on chronic maintenance hemodialysis. Nephrourol Mon 5(2):733–735CrossRefPubMedPubMedCentral

Titel: Levels of cystatin C in low- and high-flux hemodialysis in children with end-stage renal disease
verfasst von: Fatina I. Fadel
Abbass A. Mourad
Azza M. O. Abdel Rahman
Hafez M. Bazaraa
Mohamed Farouk Mohamed
Dalia H. El-Lebedy
Mohamed M. Soliman
Publikationsdatum: 17.04.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Pediatric Nephrology / Ausgabe 9/2017
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-017-3661-0

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Levels of cystatin C in low- and high-flux hemodialysis in children with end-stage renal disease